Online citations, reference lists, and bibliographies.
← Back to Search

Nanosizing--oral Formulation Development And Biopharmaceutical Evaluation.

F. Kesisoglou, S. Panmai, Y. Wu
Published 2007 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Poor aqueous solubility represents a major hurdle in achieving adequate oral bioavailability for a large percentage of drug compounds in drug development nowadays. Nanosizing refers to the reduction of the active pharmaceutical ingredient (API) particle size down to the sub-micron range, with the final particle size typically being 100-200 nm. The reduction of particle size leads to a significant increase in the dissolution rate of the API, which in turn can lead to substantial increases in bioavailability. This review describes the principles behind nanosizing, the production and characterization of nanoformulations as well as the current experience with utilization of such formulations in vivo.
This paper references
10.1081/DDC-52182
Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound
P. Langguth (2005)
10.1016/J.IJPHARM.2003.12.021
Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs.
D. Euler (2004)
10.1016/J.JCONREL.2005.11.013
Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Jun-ichi Jinno (2006)
10.1016/S0928-0987(00)00167-6
Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.
C. Pouton (2000)
10.1016/J.EJPB.2006.01.006
Single dose and multiple dose studies of itraconazole nanoparticles.
J. M. Vaughn (2006)
10.1002/JPS.10272
Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle.
L. Jia (2003)
10.1038/nrd1494
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
10.1515/zpch-1904-4705
Reaktionsgeschwindigkeit in heterogenen Systemen
E. Brunner (1904)
10.1016/S0378-5173(97)00311-6
Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique
R. Mueller (1998)
10.1128/AAC.00630-06
Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation
J. Mouton (2006)
10.1093/JAC/45.1.77
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
K. Peters (2000)
10.1021/JA02086A003
The rate of solution of solid substances in their own solutions
A. A. Noyes (1897)
10.1016/J.EJPB.2006.05.008
Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
J. Hecq (2006)
10.1016/S0378-5173(02)00686-5
Formulation of amphotericin B as nanosuspension for oral administration.
O. Kayser (2003)
10.1515/ZPCH-1904-4704
Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen
W. Nernst (1904)
10.1016/J.IJPHARM.2004.08.001
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Y. Wu (2004)
10.1016/0169-409X(96)00009-9
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
L. X. Yu (1996)
10.1016/0378-5173(95)00033-F
The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs
M. Mosharraf (1995)
10.1177/0091270005283467
Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers
Anup K. Majumdar (2006)
10.1038/208529b0
Particle Size Measurement
T. Allen (1965)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.1016/J.IJPHARM.2006.01.008
Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
P. Kocbek (2006)
10.1016/J.EJPB.2005.05.009
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
C. Keck (2006)
10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
10.1016/J.ADDR.2006.09.017
Freeze-drying of nanoparticles: formulation, process and storage considerations.
W. Abdelwahed (2006)
10.1016/S0378-5173(99)00434-2
Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages.
O. Kayser (2000)
10.1002/JPS.2600750313
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans.
C. Y. Lui (1986)
10.1208/pt070118
Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid
J. L. H. Johnson (2008)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/J.BIOPHA.2004.02.001
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
R. N. Gursoy (2004)
10.1016/J.COCIS.2004.06.009
Current strategies for engineering drug nanoparticles
A. Date (2004)
10.1016/0927-7757(93)80276-K
Foundations of Colloid Science
R. Hunter (1987)
10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
Poor aqueous solubility-an industry wide problem in drug discovery
C. Lipinski (2002)
10.1016/J.CES.2005.02.057
Nanomilling in stirred media mills
F. Stenger (2005)
10.1023/A:1019829622088
Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry
L. Jia (2004)
10.1016/S0928-0987(03)00203-3
Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems.
Jiahui Hu (2003)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1080/03639040500529176
Supersaturation Produces High Bioavailability of Amorphous Danazol Particles Formed by Evaporative Precipitation into Aqueous Solution and Spray Freezing into Liquid Technologies
J. M. Vaughn (2006)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)



This paper is referenced by
10.1002/jps.21630
Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.
N. El-gendy (2009)
10.1016/j.addr.2009.11.023
New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
A. Sosnik (2010)
Comparative In vivo Evaluation of Aripiprazole Coprecipitate, Nanoparticles and Marketed Tablets in Healthy Human Volunteers and In vitro-In vivo Correlation
A. Abdelbary (2011)
Production de particules presque monodispersées à l'aide d'un broyage et d'une séparation à membrane.
José Luis Santos (2013)
A REVIEW ON DRIED NANOSUSPENSIONS- A NOVEL FORMULATION TO ENHANCE SOLUBILITY OF POORLY AQUEOUS SOLUBLE DRUGS
Sureddi V. Lakshmi (2014)
10.1016/j.ajps.2018.04.002
Amino functionalized chiral mesoporous silica nanoparticles for improved loading and release of poorly water-soluble drug
X. Wang (2019)
Development of nanofibrous membranes for enzymatic food processing
M. Mason (2017)
NANOSUSPENSIONS: A STRATEGY FOR IMPROVED BIOAVAILABILITY
S. Pattnaik (2013)
10.18433/J3PW2W
Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
Xiaoqing Miao (2011)
Nanodispersions Platform for Solubility Improvement
Ezeddin Kolaib (2013)
Investigating the Effect of Mixed Surfactants with Different HLBs on the Properties of Solid Lipid Nanoparticle of Spironolactone
Zhila Imani (2018)
10.2174/187640290504131127121625
Nanosuspension: A Potential Nanoformulation for Improved Delivery of Poorly Bioavailable Drug
M. A. Rahman (2013)
10.3390/pharmaceutics12040363
Influence of Formulation Parameters on Redispersibility of Naproxen Nanoparticles from Granules Produced in a Fluidized Bed Process
Martin Wewers (2020)
10.1007/s13346-018-00596-w
Domperidone nanocrystals with boosted oral bioavailability: fabrication, evaluation and molecular insight into the polymer-domperidone nanocrystal interaction
Stalielson Tatenda Ndlovu (2018)
10.1016/j.toxlet.2017.09.005
Toxicology studies of primycin-sulphate using a three-dimensional (3D) in vitro human liver aggregate model.
Ágota Pénzes (2017)
10.2147/JEP.S214417
Evaluation of the antidiarrheal activity of the leaf extract of Parquetina nigrescens and formulation into oral suspensions
A. Kola-Mustapha (2019)
10.1016/j.ejpb.2015.11.011
Effect of polymer species and concentration on the production of mefenamic acid nanoparticles by media milling.
Atsutoshi Ito (2016)
10.1016/J.POWTEC.2016.09.073
Ultrafine clarithromycin nanoparticles via anti-solvent precipitation in subcritical water: Effect of operating parameters
Yuan Pu (2017)
10.1016/j.ijpharm.2013.06.050
Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property.
P. Yue (2013)
10.3109/1061186X.2011.645161
A mini review of nanosuspensions development
Y. Liu (2012)
10.1016/j.biomaterials.2010.12.011
Drug permeation across intestinal epithelial cells using porous silicon nanoparticles.
Luis M Bimbo (2011)
Stabilizers used in nanocrystal based drug delivery systems
G. Shete (2014)
10.1021/acs.cgd.5b00072
Spray Sonocrystallization
Hyo Na Kim (2015)
10.1002/jin2.41
Novel nanosuspension‐based dissolving microneedle arrays for transdermal delivery of a hydrophobic drug
Lalit Vora (2018)
10.1016/j.ijpharm.2012.05.076
Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Qing-Ri Cao (2012)
10.1016/j.ijpharm.2014.05.003
A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology.
Dennis H Leung (2014)
10.1016/j.ejps.2013.09.002
Impact of process parameters on the breakage kinetics of poorly water-soluble drugs during wet stirred media milling: a microhydrodynamic view.
A. Afolabi (2014)
10.1016/j.ijpharm.2017.07.065
Non-invasive strategies for targeting the posterior segment of eye.
Asadullah Madni (2017)
10.1021/ACS.CGD.5B00662
Investigation of the Particle Growth of Fenofibrate following Antisolvent Precipitation and Freeze–Drying
Teresa B. Tierney (2015)
10.1088/0953-8984/22/45/454127
Current oscillations generated by precipitate formation in the mixing zone between two solutions inside a nanopore.
Erik C. Yusko (2010)
10.1021/ACS.CGD.6B01256
Stepwise Use of Additives for Improved Control over Formation and Stability of Mefenamic Acid Nanocrystals Produced by Antisolvent Precipitation
Katalin Bodnár (2017)
10.1016/j.micromeso.2019.109896
Amino functionalized mesoporous silica with twisted rod-like shapes: Synthetic design, in vitro and in vivo evaluation for ibuprofen delivery
Yumei Wang (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar